Alkermes plc
NASDAQ:ALKSBiotechnology
+$0.79 today
- Market cap
- $7.87B
- Beta
- 0.33
- P/E (TTM)
- 49.1
- EPS (TTM)
- $0.92
Volume 1.39M
Average 2.33M
ALKS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Alkermes plcNASDAQ: ALKS
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents rises 2.4% from a year ago
Cash & equivalents stood at $631.31M at the end of Q3 FY2026, up 2.4% from a year earlier and up 23.4% from the prior quarter. Over 3 fiscal years it compounded at +56.4% a year.
Context
- Cash & equivalents amounted to 14.2% of total assets at the end of Q3 FY2026, down 12.2 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +2.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 1.12B USD
- Year-over-year change
- +284.6%
- 4-year CAGR
- +35.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.12B | +284.6% |
| FY2024 | 2024-12-31 | 291.15M | -36.4% |
| FY2023 | 2023-12-31 | 457.47M | +56.4% |
| FY2022 | 2022-12-31 | 292.47M | -13.4% |
| FY2021 | 2021-12-31 | 337.54M | — |
Cash & Equivalents vs competitors
How ALKS compares with its peers on the latest reported figures
- ALKS's Sep 2026 cash & equivalents of $631.31M is the 4th highest of the 7 companies compared; the peer median is $480.68M.
- Its year-over-year change of +2.4% is the 6th highest of 7, against a peer median of +44.6%.
- Cash & equivalents amounts to 14.2% of total assets for ALKS, versus a peer median of 14.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $2.04B | +64.7% | +16.4% | 17.0% | |
| Sep 2026 | $976.45M | +278.5% | +15.7% | 54.4% | |
| Sep 2026 | $641.5M | +88.6% | +39.5% | 11.4% | |
| Sep 2026 | $631.31M | +2.4% | +56.4% | 14.2% | |
| Jun 2026 | $319.85M | +5.6% | +17.2% | 42.0% | |
| Jun 2026 | $179.95M | +24.4% | +11.3% | 12.6% | |
| Mar 2026 | $54.03M | -51.7% | -14.3% | 12.5% | |
| Peer median (excluding ALKS) | $480.68M | +44.6% | +16.1% | 14.8% | |
Competitors are the stored peer set for ALKS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 337.54M | 292.47M | 457.47M | 291.15M | 1.12B |
| Short-term Investments | 198.77M | 315.99M | 316.02M | 460.52M | 199.65M |
| Net Receivables | 326.56M | 296.9M | 333.18M | 389.52M | 334.03M |
| Inventory | 150.34M | 181.42M | 186.41M | 182.89M | 196.63M |
| Other Current Assets | 0 | 43.53M | 192.43M | 91.28M | 79.09M |
| Total Current Assets | 1.06B | 1.13B | 1.49B | 1.42B | 1.93B |
| Property, Plant & Equipment (Net) | 456.68M | 320.46M | 318.4M | 311.81M | 298.93M |
| Goodwill | 92.87M | 83.03M | 83.03M | 83.03M | 0 |
| Intangible Assets | 74.04M | 37.68M | 1.99M | 890K | 83.84M |
| Long-term Investments | 229.43M | 131.61M | 39.89M | 73.15M | 145K |
| Tax Assets | 81.83M | 114.57M | 195.89M | 154.84M | 169.08M |
| Other Non-current Assets | 27.46M | 146.33M | 11.52M | 16.5M | 49.1M |
| Total Non-current Assets | 962.32M | 833.67M | 650.72M | 640.21M | 601.09M |
| Total Assets | 2.02B | 1.96B | 2.14B | 2.06B | 2.53B |
| Account Payables | 55.72M | 32.84M | 65.65M | 45.63M | 107.95M |
| Short-term Debt | 3M | 3M | 3M | 0 | 6.75M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 6.34M | 6.82M | 2.73M | 1.25M | 0 |
| Other Current Liabilities | 77.26M | 84.93M | 359.99M | 70.96M | 346.29M |
| Total Current Liabilities | 471.29M | 497.74M | 520.22M | 465.2M | 543.44M |
| Long-term Debt | 292.8M | 290.27M | 287.73M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | (4.78M) | 0 | 43.26M |
| Deferred Revenue (Non-current) | 11.49M | 0 | 4.78M | 1.25M | 0 |
| Other Non-current Liabilities | 32.16M | 55.93M | 49.88M | 54.77M | 61.01M |
| Total Non-current Liabilities | 440.61M | 422.48M | 413.32M | 125.39M | 167.52M |
| Total Liabilities | 911.9M | 920.23M | 933.54M | 590.59M | 710.96M |
| Common Stock | 1.66M | 1.69M | 1.73M | 1.77M | 1.81M |
| Retained Earnings | (1.54B) | (1.7B) | (1.34B) | (976.46M) | (734.79M) |
| Accumulated OCI | (3.72M) | (10.89M) | (3.11M) | (1.97M) | (2.1M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.11B | 1.04B | 1.2B | 1.46B | 1.82B |
| Total Debt | 416.21M | 379.44M | 372.19M | 75.54M | 70M |
| Net Debt | 78.66M | 86.96M | (85.28M) | (215.61M) | (1.05B) |
Alkermes plc
NASDAQ:ALKS
Intrinsic Alpha fair value
Locked
Current Price
$46.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.